
SNU-5-FGFR2b no expression cell
Inhibition Rate (%)
120
110
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
100 nM
10 nM
1 nM
Human IgG1 isotype control
FPA144
HC18-deruxtecan
Staurosporine

FIG. 1


SNU-16-FGFR2b middle expression cell
Inhibition Rate (%)
120
110
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
100 nM
10 nM
1 nM
IgG1 isotype control
FPA144
HC18-deruxtecan
Staurosporine

FIG. 2


SNU-16-FGFR2b middle expression gastric cancer cell
Tumor Volume (mm3)
1200
1000
800
600
400
200
0
0 3 6 9 12 15 18 21 24 27 30 33 36
Days after the start of treatment
Vehicle, IV, Single dose
Human IgG1 isotype ADC control-Dxd,10 mg/kg,IV,single dose
FPA144,10mg/kg, IV, Single dose
HC18-deruxtecan,10mg/kg, IV, Single dose

FIG. 3


SNU-16-FGFR2b middle expression gastric cancer cell
Body Weight (g)
30
29
28
27
26
25
24
23
22
21
20
19
18
0 3 6 9 12 15 18 21 24 27 30 33 36
Days after the start of treatment
Vehicle,IV,single dose
Human IgG1 isotype ADC control-Dxd,10 mg/kg,IV,single dose
FPA144,10 mg/kg,IV,single dose
HC18-deruxtecan,10 mg/kg,IV,single dose

FIG. 4


SNU-16-FGFR2b middle expression gastric cancer cell
Tumor Volume (mm3)
500
400
300
200
100
0
0
7
14
21
28
Days after the start of treatment
Vehicle,IV,single dose
HC18-deruxtecan,1 mg/kg,IV,single dose
HC18-deruxtecan,3 mg/kg,IV,single dose
HC18-01-deruxtecan,1 mg/kg,IV,single dose
HC18-01-deruxtecan,3 mg/kg,IV,single dose
HC18-01-ADC2,1 mg/kg,IV,single dose
HC18-01-ADC2,3 mg/kg,IV,single dose
HC18-01-ADC1,1 mg/kg,IV,single dose
HC18-01-ADC1,3 mg/kg,IV,single dose
HC18-01-ADC3,1 mg/kg,IV,single dose
HC18-01-ADC3,3 mg/kg,IV,single dose

FIG. 5


SNU-16-FGFR2b middle expression gastric cancer cell
Body Weight (g)
30
29
28
27
26
25
24
23
22
21
20
19
18
0
7
14
21
28
Days after the start of treatment
Vehicle,IV,single dose
HC18-deruxtecan,1 mg/kg,IV,single dose
HC18-deruxtecan,3 mg/kg,IV,single dose
HC18-01-deruxtecan,1 mg/kg,IV,single dose
HC18-01-deruxtecan,3 mg/kg,IV,single dose
HC18-01-ADC2,1 mg/kg,IV,single dose
HC18-01-ADC2,3 mg/kg,IV,single dose
HC18-01-ADC1,1 mg/kg,IV,single dose
HC18-01-ADC1,3 mg/kg,IV,single dose
HC18-01-ADC3,1 mg/kg,IV,single dose
HC18-01-ADC3,3 mg/kg,IV,single dose

FIG. 6


Tumor Volume (mm3)
1400
1200
1000
800
600
400
200
0
0
7
14
21
28
35
42
49
Days After Treatment Start
**
***
****
#
^^
Vehicle
HC18-01-ADC1 0.5 mg/kg
HC18-01-ADC1 1 mg/kg
HC18-01-ADC1 3 mg/kg
HC18-01-ADC1 10 mg/kg
Bemarituzumab 10 mg/kg
**p<0.01 and ****p<0.0001 vs Vehicle,
#p<0.05 vs HDM2020 0.5 mg/kg,
^^p<0.01 vs Bemarituzumab
One-way ANOVA
Administration

FIG. 7


Body Weight Change (%)
15
10
5
0
-5
-10
-15
0
7
14
21
28
35
42
49
Days After Treatment Start
Vehicle
HC18-01-ADC1 0.5 mg/kg
HC18-01-ADC1 1 mg/kg
HC18-01-ADC1 3 mg/kg
HC18-01-ADC1 10 mg/kg
Bemarituzumab 10 mg/kg
Administration

FIG. 8


Tumor Volume (mm3)
2400
2100
1800
1500
1200
900
600
300
0
0 7 14 21 28 35 42 49 56 63
Days After Treatment Start
Vehicle
HC18-01-ADC1 0.4 mg/kg
HC18-01-ADC1 2 mg/kg
HC18-01-ADC1 10 mg/kg
HC18-01 10 mg/kg
Bemarituzumab 10 mg/kg
***
****
****
****
^^^
****p<0.0001 vs Vehicle,
^^^p<0.001 vs HDM2020 0.4 mg/kg
and PM-012C 10 mg/kg
One-way ANOVA
Administration

FIG. 9


Body Weight Change (%)
15
10
5
0
-5
-10
-15
0 7 14 21 28 35 42 49 56 63
Days After Treatment Start
Vehicle
HC18-01-ADC1 0.4 mg/kg
HC18-01-ADC1 2 mg/kg
HC18-01-ADC1 10 mg/kg
HC18-01 10 mg/kg
Bemarituzumab 10 mg/kg
Administration

FIG. 10


Tumor Volume (mm3)
2400
2100
1800
1500
1200
900
600
300
0
0 7 14 21 28 35 42 49 56 63
Days After Treatment Start
Vehicle
HC18-01-ADC1 0.4 mg/kg
HC18-01-ADC1 2 mg/kg
HC18-01-ADC1 10 mg/kg
HC18-01 10 mg/kg
Bemarituzumab 10 mg/kg
Paclitaxel 10 mg/kg
^^^
***
****
****
Single Dose Administration
Paclitaxel Administration

FIG. 11


Tumor Weight (g)
2.5
2.0
1.5
1.0
0.5
0.0
###
#
####
****
****
****
****
****
Vehicle
HC18-01-ADC1 0.4 mg/kg
HC18-01-ADC1 2 mg/kg
HC18-01-ADC1 10 mg/kg
HC18-01 10 mg/kg
Bemarituzumab 10 mg/kg
Paclitaxel 10 mg/kg

FIG. 12


Tumor Volume (mm3)
2100
1800
1500
1200
900
600
300
0
0
7
14
21
28
35
42
Days After Treatment Start
Vehicle
HC18-01-ADC1 3 mg/kg
HC18-01-ADC1 10 mg/kg
Bemarituzumab 10 mg/kg
Docetaxel 10 mg/kg
***#
****
***#
Single dose administration
QW*4 weeks administration

FIG. 13


Tumor weight (g)
0.8
0.6
0.4
0.2
0.0
&&
&
HC18-01-ADC1 3 mg/kg
HC18-01-ADC1 10 mg/kg
Docetaxel 10 mg/kg

FIG. 14